GlassScriptPhysician profile
Lyle C Myers
NPI 1255493342
$59,888.42
in general payments reported to CMS, 2019-2025
49 companies · $459 in 2025
The $459 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $14K · 2021: $2,278 · 2022: $1,741 · 2023: $1,592 · 2024: $421 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,472.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $19,043.27 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16,832.54 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $7,421.50 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $5,836.60 | 2019-2023 | Jardiance, Mounjaro |
| Merck Sharp & Dohme LLC | $3,997.58 | 2019-2025 | Zerbaxa |
| Novo Nordisk INC | $1,047.59 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $779.33 | 2019-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $724.36 | 2019-2023 | Freestyle Libre 3 |
| Mannkind Corporation | $702.32 | 2019-2023 | Afrezza |
| Medtronic, INC. | $553.88 | 2021-2025 | Minimed 780g, Minimed 770g |
| Amarin Pharma, INC. | $391.02 | 2019-2021 | |
| Abbvie INC. | $352.89 | 2019-2023 | |
| Xeris Pharmaceuticals, INC. | $226.01 | 2020-2023 | Gvoke Hypopen |
| Insulet Corporation | $171.66 | 2020-2024 | Omnipod |
| Amgen INC. | $162.78 | 2019-2023 | Repatha |
Show all 47 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lyle Myers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.